NCT01438177 · REGISTRY CONDITION SEARCH

Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: TERMINATED
Registry last update: 2020-02-24

This pilot phase II trial studies how well giving bortezomib and cyclophosphamide together with chloroquine works in treating patients with relapsed or refractory multiple myeloma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Response Rate (CR + PR After 2 Cycles)

→

outcome · POSTED

Number of Participants With Adverse Events of Grade 3 or Higher

→

outcome · POSTED

Percentage of Subjects Who Have Complete Response or Partial Response and Have 2+ or Higher Autophagy

→

outcome · POSTED

Median Duration of Response of This Regimen

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: 1. Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. 2. Female subject is either post-menopausal for at least 1 year before the screening visit, is surgically sterilized or if they are of childbearing potential, agree to practice 2 effective methods of contraception from the time of signing the informed consent form through 30 days after the last dose of VELCADE, or agree to completely abstain from heterosexual intercourse. Male subjects, even if surgically sterilized (ie, status postvasectomy) must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourse. 3. Diagnosis of multiple myeloma based on standard criteria as follows: Major Criteria: I. Plasmacytomas on tissue biopsy II. Bone marrow plasmacytosis (\>30% plasma cells) III. Monoclonal immunoglobulin spike on serum electrophoresis (IgG \>3.5 G/dL or IgA \> 2.0 G/dL) or kappa or lambda light chain excretion\> 1 G/day on 24 hour urine protein electrophoresis Minor Criteria 1. Bone marrow plasmacytosis (10 to 30% plasma cells) 2. Monoclonal immunoglobulin present but of lesser magnitude than given under major criteria 3. Lytic bone lesions 4. Normal IgM \< 50 mg/dL, IgA \< 100 mg/dL, or IgG \< 600 mg/dL Any of the following sets of criteria will confirm the diagnosis of Multiple Myeloma: * Any two of the major criteria * Major criterion I plus minor criterion b, c, or d * Major criterion III plus minor criterion a or c * Minor criteria a, b and c or a, b and d 4. Measurable disease, defined as a monoclonal immunoglobulin spike on serum electrophoresis of ≥ 1 Gm/dL and/or urine monoclonal immunoglobulin spike of ≥ 200 mg/24 hours. 5. Patients must have refractory myeloma as defined by a greater than 25% increase in their M-protein. They should have progressed on a combination of VELCADE and cyclophosphamide. 6. Non-secretors must have measurable protein by Freelite or measurable disease such as plasmacytoma to be eligible. 7. Karnofsky performance status ≥ 50 8. Patients treated with local radiotherapy with or without a brief exposure to steroids are eligible. Patients who require concurrent radiotherapy should have entry to the protocol deferred until the radiotherapy is completed 9. Meets the following pretreatment laboratory criteria at Baseline (Day 1 of Cycle 1, before study drug administration) * Absolute neutrophil count ≥ 0.5 x 10\^3/uL * Calculated or measured creatinine clearance ≥ 30 mL/min 10. Age 18 years or older Exclusion Criteria: 1. POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein (M-protein) and skin changes) 2. Plasma cell leukemia 3. Receiving steroids daily for other medical conditions, e.g., asthma, systemic lupus erythematosis, rheumatoid arthritis 4. Infection not controlled by antibiotics 5. HIV infection. Patients should provide consent for HIV testing according to the institution's standard practice 6. Known active hepatitis B or C 7. Patient had myocardial infarction within 6 months prior to enrollment, New York Hospital Association (NYHA) Class III or IV heart failure, (see appendix D), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening must be documented by the investigator as not medically relevant. 8. Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy. 9. Radiation therapy within 3 weeks before randomization. Enrollment of subjects who require concurrent radiotherapy (which must be localized in its field size) should be deferred until the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy. 10. Other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol 11. Female subject is pregnant or lactating. Confirmation that the subject is not pregnant must be established by a negative serum B-human chorionic gonadotropin (B hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for postmenopausal or surgically sterilized women. 12. Patient has \> Grade 2 peripheral neuropathy 13. Patient has known hypersensitivity to VELCADE, boron or mannitol, quinidine or quinidine derivatives or to cyclophosphamide or any component of the formulation. 14. Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial. 15. Patients with preexisting retinal or visual field changes. 16. Patient has \> 1.5 x upper limit of normal Total Bilirubin
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
VELCADE given by intravenous push at 1.3 mg/m\^2 on days 1, 4, 8, 11, 22, 25, 29 and 32. Cyclophosphamide given at 50 mg orally twice per day on days 1-14 and 22-35. Chloroquine given at 500 mg orally daily on days 1-14 and 22-35. Each cycle is 42 days in length.
intervention Names
Drug: Velcade
Drug: Cyclophosphamide
Drug: Chloroquine
label
Velcade+Cyclophosphamide+Chloroquine
type
EXPERIMENTAL

interventions

arm Group Labels
Velcade+Cyclophosphamide+Chloroquine
name
Velcade
other Names
Bendamustine HCl
Treanda
Bortezomib
type
DRUG
arm Group Labels
Velcade+Cyclophosphamide+Chloroquine
name
Cyclophosphamide
other Names
Cytoxan
Neosar
Endoxan
Revimmune
Procytox
type
DRUG
arm Group Labels
Velcade+Cyclophosphamide+Chloroquine
name
Chloroquine
other Names
Aralen
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 11
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Response rate is defined as the percentage of patients who have a complete response (CR) or partial response (PR). Responses were assessed every two cycles of treatment, based on the criteria published by the International Myeloma Working Group (Durie, et al, 2006). Per International Myeloma Working Group response criteria: CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \< 5% plasma cells in bone marrow PR: \> 50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by \>90% or to \< 200 mg/24 h
measure
Response Rate (CR + PR After 2 Cycles)
time Frame
Up to 2 years

secondary Outcomes

description
Adverse events reported here were at least possibly related to the protocol therapy.
measure
Number of Participants With Adverse Events of Grade 3 or Higher
time Frame
Treatment period plus 30 days post-treatment
measure
Percentage of Subjects Who Have Complete Response or Partial Response and Have 2+ or Higher Autophagy
time Frame
until clinical response (up to 2 years)
description
Duration of response is the time from response (CR or PR) until progression of disease or relapse. Responses and progression were evaluated based on the criteria published by the International Myeloma Working Group (Durie, et al, 2006).
measure
Median Duration of Response of This Regimen
time Frame
up to 2 years

Full study description

brief Summary: This pilot phase II trial studies how well giving bortezomib and cyclophosphamide together with chloroquine works in treating patients with relapsed or refractory multiple myeloma.
detailed Description: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chloroquine may help chemotherapy drugs work better by making cancer cells more sensitive to the drug. Giving bortezomib and cyclophosphamide together with chloroquine may kill more cancer cells.

Source references

references

citation
Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006 Sep;20(9):1467-73. doi: 10.1038/sj.leu.2404284. Epub 2006 Jul 20.
pmid
16855634
type
BACKGROUND

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-aaa70b27822d4894fb26
requested nct id
NCT01438177
primary nct id
NCT01438177
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
d0b53c1436a8d1571ee871cd8d8b9d1429c6a414ec20b7a75d201e43ea17ba4a
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-aaa70b27822d4894fb26
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01438177
occurrences
context exact
NCT01438177
end
11
exact text
NCT01438177
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/941/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
9d8b139cdf3aba77ed2e7192adf5039e625c30b2723908a2530a82f73cf5e960
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice